Please assess the completion status of the following clinical trial:

Trial Title: Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria :~* Participants with bilateral sino-nasal polyposis that despite prior treatment with SCS anytime within the past 2 years; and/or had a medical contraindication/intolerance to SCS; and/or had prior surgery for NP at the screening visit, had:~* An endoscopic bilateral NPS at Visit 1 (V1) of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).~* Ongoing symptoms (for at least 8 weeks before V1) of NC/blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).~* Signed written informed consent.~Exclusion criteria:~* Participants \<18 years of age.~* Participant who had been previously treated in dupilumab studies.~* Participant who had taken:~  * Biologic therapy/ systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever was longer.~ * Any experimental monoclonal antibody within 5 half-lives or within 6 months before V1 if the half-life was unknown.~ * Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1.~ * Participants who received leukotriene antagonists/modifiers at V1 unless they were on a continuous treatment for at least 30 days prior to V1.~* Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period.~* Participants who underwent any and/or sinus surgery (including polypectomy) within 6 months before V1.~* Participants who had a sino-nasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.~* Participants with conditions/concomitant diseases making them non evaluable at V1 or for the primary efficacy endpoint such as:~  * Antrochoanal polyps,~ * Nasal septal deviation that would occlude at least one nostril,~ * Acute sinusitis, nasal infection or upper respiratory infection,~ * Ongoing rhinitis medicamentosa,~ * Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener's granulomatosis),Young's syndrome, Kartagener's syndrome or other dyskinetic ciliary syndromes, concomitant cystic fibrosis,~ * Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.~* Participants with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc.).~* Participants with forced expiratory volume 50% or less (of predicted normal).~* Participants who received concomitant treatment prohibited in the study.~* Treatment with a live (attenuated) vaccine within 4 weeks before the baseline visit.~* Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.~* History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.~* Positive with hepatitis B surface antigen or hepatitis C antibody at the screening visit.~* Active chronic or acute infection requiring systemic treatment within 2 weeks before the baseline visit.~* Known or suspected history of immunosuppression.~* Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.~* Women unwilling to use adequate birth control, if of reproductive potential and sexually active.~The above information was not intended to contain all considerations relevant to a Participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dupilumab 300 mg q2w (Type: EXPERIMENTAL): Dupilumab 300 mg subcutaneous (SC) injection q2w from Day 1 of Week 0 up to Week 52 added to background therapy of intranasal MFNS at stable dose.
- Dupilumab 300 mg q2w then q4w (Type: EXPERIMENTAL): Dupilumab 300 mg SC injection q2w from Day 1 of Week 0 up to Week 24 and then 300 mg q4w until Week 52 added to background therapy of intranasal MFNS at stable dose. After Week 24, Dupilumab administration was alternated with matched placebo injection every other week up to Week 50.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (for dupilumab), 1 SC injection q2w from Day 1 of Week 0 up to Week 52 added to background therapy of intranasal MFNS at stable dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).